Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris Inc. reports developments in synthetic biology, industrial biotechnology, and precision fermentation for renewable specialty ingredients. Company updates center on proprietary fermentation technology, the Barra Bonita precision fermentation plant in Brazil, ingredient commercialization, and partner arrangements for products such as fermented Reb M and sustainable squalene.
Recurring Amyris news also covers operating and financial results, cost and capital-structure initiatives, governance changes, and restructuring activity tied to its business transformation. The company's announcements describe how its technology platform, manufacturing assets, and licensing or supply relationships support specialty-ingredient production for consumer, food, pharmaceutical, and related markets.
Amyris, a leader in synthetic biotechnology, will present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on September 14, 2020, at 10:00 a.m. ET. CEO John Melo will discuss the company's performance and progress, with a live webcast available on its investor relations website. Amyris specializes in sustainable ingredients for Clean Health and Beauty markets, owning three consumer brands: Biossance, Pipette, and Purecane. The presentation will not include a Q&A session.
Amyris, Inc. (Nasdaq: AMRS) has successfully scaled up the commercial production of Cannabigerol (CBG) using its fermentation process. The company expects to deliver one ton of high purity CBG this year, anticipating first commercial revenue from its sale. CBG, known for its therapeutic potential, is produced at a lower cost with higher purity than traditional methods. Amyris reports that CBG shows superior efficacy in topical applications compared to CBD. This marks the tenth product developed at scale through its biotechnology platform, underscoring its growth strategy in sustainable ingredient production.
Amyris, Inc. (Nasdaq: AMRS) has appointed Sheila Shekar Pollak as the new Chief Marketing Officer for its Biossance™ Clean Beauty skincare brand. Pollak, with a strong background in brand strategy from her prior role at Athleta, aims to enhance the growth and brand value of Biossance. CEO John Melo expressed confidence in Pollak's ability to drive sales, which are anticipated to reach record highs this quarter. Pollak is excited to align her sustainability-focused vision with Biossance's commitment to clean beauty.
Amyris, Inc. (Nasdaq: AMRS) announces its Q2 2020 financial results, achieving a record revenue of $26 million in Consumer & Ingredients, more than doubling year-over-year. The company completed a $200 million private placement, reducing debt by $121 million (40%) since the start of 2020, which will lower cash servicing costs by $30 million in H2 2020. EBITDA improved, with cash operating expenses dropping to $43 million, the lowest in five quarters. Amyris signed partnerships for Purecane™ in baking and an RNA vaccine platform.
Amyris has partnered with the Infectious Disease Research Institute (IDRI) to develop a COVID-19 RNA vaccine using its sustainable fermentation technology. This collaboration aims to create semi-synthetic squalene-based adjuvants, enhancing vaccine efficacy while addressing supply issues related to traditional shark-derived squalene. IDRI's innovative RNA vaccine platform is anticipated to offer significant advantages over existing vaccines. The companies expect to commercialize their adjuvant by end of this year, with potential for a vaccine by next year, emphasizing their commitment to tackling global pandemics.
Amyris, a leader in synthetic biotechnology, will host a conference call on August 6, 2020, at 6:00 a.m. PT to discuss its second quarter 2020 results. The financial results will be released in the morning before the call. Key executives, including CEO John Melo and CFO Han Kieftenbeld, will provide insights into the company’s financial performance and future strategy. Interested parties can join the call by dialing (888) 567-1603 or accessing a live webcast at the company’s website.
On July 15, 2020, Amyris announced the launch of Biosilica™, a sustainable plant-derived silica sourced from sugarcane ashes. This innovation, commercialized by Aprinnova, offers an eco-friendly alternative to traditional silica, often derived from non-renewable resources. Biosilica™ is intended for use in various cosmetic products and aims to meet the growing consumer demand for clean beauty ingredients. Consumer studies indicate improved performance in cosmetics made with Biosilica™ compared to conventional silica. The ingredient will be available for sampling in August, with commercial volumes expected to roll out in 2021.
Biossance, a clean skincare brand from Amyris (Nasdaq: AMRS), has launched The Clean Academy Impact Award to recognize sustainability leaders. The initiative debuted on June 29, 2020, during a digital event, with winners receiving $10,000 and mentorship. U.S. residents aged 18 and above can apply by July 29, 2020. The award aims to support projects focused on ocean protection, in partnership with Oceana. Biossance promotes sustainable practices, utilizing vegan squalane derived from sugarcane, and aligns with Oceana's mission to restore marine biodiversity.